ceftobiprole medocaril + Vancomycin plus Ceftazidime
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Diseases, Infectious
Conditions
Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections
Trial Timeline
Sep 1, 2005 → Oct 1, 2006
NCT ID
NCT00210899About ceftobiprole medocaril + Vancomycin plus Ceftazidime
ceftobiprole medocaril + Vancomycin plus Ceftazidime is a phase 3 stage product being developed by Basilea Pharmaceutica for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00210899. Target conditions include Skin Diseases, Infectious, Skin Diseases, Bacterial, Staphylococcal Skin Infections.
What happened to similar drugs?
16 of 20 similar drugs in Skin Diseases, Infectious were approved
Approved (16) Terminated (4) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00210899 | Phase 3 | Completed |
Competing Products
20 competing products in Skin Diseases, Infectious